We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
RETEVMO (Eli Lilly Australia Pty Ltd)
Product name
RETEVMO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
187 (255 working days)
Active ingredients
selpercatinib
Registration type
EOI
Indication
RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.